Breakthrough Eye Drop Treatment for Common Eye Diseases Announced
AThe inherited retinal disease (IRD) community often faces the challenges of progressive vision loss and the search for effective treatments. While inherited retinal diseases are distinct, advancements in treating other common eye conditions like macular degeneration can sometimes offer insights or pave the way for broader ophthalmic research. A recent announcement from Lorati Company Limited, a biotechnology and pharmaceutical company based in Taiwan, details the development of nano-grade eye drops designed to treat and reverse cataract, glaucoma, and macular degeneration, offering a potential new avenue in ophthalmic care.
According to a press release from May 4, 2017, Lorati Company Limited has successfully developed nano-grade eye drops. These eye drops are intended to effectively treat and reverse cataract, glaucoma, and macular degeneration. David Lo, CEO of Lorati, stated that these nano-grade eye drops are based on montmorillonite, also known as God's clay. Lo reportedly believes this treatment could be a